These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23715382

  • 1. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
    Xi L, Zhang JQ, Liu ZC, Zhang JH, Yan JF, Jin Y, Lin J.
    Org Biomol Chem; 2013 Jul 14; 11(26):4367-78. PubMed ID: 23715382
    [Abstract] [Full Text] [Related]

  • 2. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
    Zhang HQ, Gong FH, Li CG, Zhang C, Wang YJ, Xu YG, Sun LP.
    Eur J Med Chem; 2016 Feb 15; 109():371-9. PubMed ID: 26826581
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.
    ChemMedChem; 2013 Jun 15; 8(6):928-33. PubMed ID: 23640754
    [Abstract] [Full Text] [Related]

  • 6. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ.
    Eur J Med Chem; 2014 Jan 15; 71():1-14. PubMed ID: 24269511
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking.
    Zhao Y, Liu F, He G, Li K, Zhu C, Yu W, Zhang C, Xie M, Lin J, Zhang J, Jin Y.
    Bioorg Med Chem Lett; 2019 Dec 01; 29(23):126711. PubMed ID: 31668972
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4529-35. PubMed ID: 21724404
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S, Barczyk A, Six P, Cagnon A, Garofalo A, Goossens L, Depreux P.
    Eur J Med Chem; 2014 May 22; 79():369-81. PubMed ID: 24747748
    [Abstract] [Full Text] [Related]

  • 14. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM, Serrya RA, Kafafy AH, Ahmed M, Wang F, Abouzid KA.
    J Enzyme Inhib Med Chem; 2014 Apr 22; 29(2):215-22. PubMed ID: 23402383
    [Abstract] [Full Text] [Related]

  • 15. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY, Li SN, Yu GJ, Hu QH, Li HQ.
    Bioorg Med Chem; 2013 Oct 01; 21(19):6084-91. PubMed ID: 23962660
    [Abstract] [Full Text] [Related]

  • 16. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P, Chu J, Li Y, Wang Y, He Y, Qi C, Chang J.
    Bioorg Med Chem; 2019 Oct 15; 27(20):114938. PubMed ID: 31488358
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, Yang W, Xu Y, Li M, Ding J, Jiang H, Xie H, Liu H.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7988-98. PubMed ID: 24183742
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.